
I have always questioned (based on literature similar to this) the rationale for using powerful pharmaceuticals, like the statins, for primary prevention. Primary prevention, in this case, is treating this a group of patients with no personal history or family history of heart disease, heart attacks, strokes, etc. with a medicine to lower their cholesterol when it has not been documented that there is existing atherosclerosis in this patient population. Secondary prevention has proven to lower the risk CVD occurrence, but literature does not support this notion in primary prevention.
http://www.ncbi.nlm.nih.gov/pubmed/26141958